Investors appear to be taking profits off the table after the biotech's positive Q4 update.
News & Analysis: ImmunoGen
Cost-cutting led to a surprise profit, and the company outlined the path ahead for its pipeline treatment for ovarian cancer.
The biotech handily beat Wall Street's revenue and earnings estimates.
IMGN earnings call for the period ending December 31, 2019.
Investors in the cancer-focused biotech are hoping for good news next week.
Investors appear to have renewed hopes for the biotech's experimental ovarian cancer drug.
The biotech continues to lose money, but a restructuring earlier this year put it on a better financial footing in Q3.
IMGN earnings call for the period ending September 30, 2019.
IMGN earnings call for the period ending June 30, 2019.
The clinical-stage biotech appears to be in solid financial shape as it moves toward a pivotal clinical study for its lead pipeline candidate.